We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+23.66%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.11B
AUM Growth
+$195M
(+21%)
Cap. Flow
+$57.8M
Cap. Flow
% of AUM
5.19%
Top 10 Holdings %
Top 10 Hldgs %
48.19%
Holding
72
New
18
Increased
12
Reduced
16
Closed
18
Avg Time Held
0.6
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$49.7M |
| 2 |
ENDP
Endo International plc
ENDP
|
+$46.9M |
| 3 |
ALR
Alere Inc
ALR
|
+$29.1M |
| 4 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
+$27.8M |
| 5 |
Biogen
BIIB
|
+$21.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RAD
Rite Aid Corporation
RAD
|
+$45.4M |
| 2 |
CELG
Celgene Corp
CELG
|
+$38.3M |
| 3 |
Gilead Sciences
GILD
|
+$34.7M |
| 4 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$19.4M |
| 5 |
AstraZeneca
AZN
|
+$18.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.46% |
| 2 | Miscellaneous | 10.8% |
| 3 | Financials | 2.03% |
| 4 | Technology | 1.63% |
| 5 | Communication Services | 1.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Invesco QQQ Trust
QQQ
$487B
| $454K | 0.04% |
4,300
+866
| +25% | +$90.9K |
2014 Q4
1 quarter
|
|
|
ALXN
52
DELISTED
Alexion Pharmaceuticals
ALXN
| $241K | 0.02% |
1,390
| – | – |
2014 Q4
1 quarter
|
|
53
DELISTED
ChemoCentryx, Inc.
CCXI
| $132K | 0.01% |
+17,500
| New | +$137K |
2015 Q1
0 quarters
|
|
|
54
AstraZeneca
AZN
$259B
| – | – |
-258,305
| Closed | -$18.2M | – |
|
55
DELISTED
bluebird bio
BLUE
| – | – |
-7,892
| Closed | -$9.38M | – |
|
56
eHealth
EHTH
$19.4M
| – | – |
-264,942
| Closed | -$6.6M | – |
|
57
Eledon Pharmaceuticals
ELDN
$184M
| – | – |
-1,328
| Closed | -$3.17M | – |
|
|
58
Gilead Sciences
GILD
$195B
| – | – |
-368,615
| Closed | -$34.7M | – |
|
59
iShares Biotechnology ETF
IBB
$10.6B
| – | – |
-3,000
| Closed | -$303K | – |
|
60
McKesson
MCK
$116B
| – | – |
-87,523
| Closed | -$18.2M | – |
|
61
Pacific Biosciences
PACB
$609M
| – | – |
-237,977
| Closed | -$1.87M | – |
|
62
Puma Biotechnology
PBYI
$543M
| – | – |
-93,865
| Closed | -$17.8M | – |
|
63
Universal Health Services
UHS
$11B
| – | – |
-135,270
| Closed | -$15.1M | – |
|
64
DELISTED
NEVRO CORP.
NVRO
| – | – |
-234,254
| Closed | -$9.06M | – |
|
65
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| – | – |
-119
| Closed | -$64K | – |
|
|
RAD
66
DELISTED
Rite Aid Corporation
RAD
| – | – |
-301,937
| Closed | -$45.4M | – |
|
|
WCG
67
DELISTED
Wellcare Health Plans, Inc.
WCG
| – | – |
-4,887
| Closed | -$401K | – |
|
|
FWP
68
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| – | – |
-3,605
| Closed | -$526K | – |
|
|
LOXO
69
DELISTED
Loxo Oncology, Inc
LOXO
| – | – |
-137,681
| Closed | -$1.62M | – |
|
|
CNXR
70
DELISTED
Connecture, Inc.
CNXR
| – | – |
-943,000
| Closed | -$8.5M | – |
|
|
CELG
71
DELISTED
Celgene Corp
CELG
| – | – |
-342,349
| Closed | -$38.3M | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q1 2015 Portfolio in Review
As of Q1 2015, Redmile Group held 72 positions worth $1.11B, up 21% from $918M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Redmile Group deployed $57.8M of net new capital in Q1 2015, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Teva Pharmaceutical Industries Limited: 853,973 shares worth $53.2M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was RECEPTOS INC COM STK (DE), an estimated $19.4M trimmed.
- Redmile Group's largest Q1 2015 buy was Teva Pharmaceutical Industries Limited: 853,973 shares worth $53.2M.
- Redmile Group added most to Biogen in Q1 2015, an estimated $21.5M increase.
- Redmile Group's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $19.4M.
- Redmile Group fully exited Rite Aid Corporation in Q1 2015, selling an estimated $45.4M.
- Redmile Group's ten largest holdings make up 48% of its $1.11B portfolio in Q1 2015.
- Redmile Group opened 18 new positions and closed 18 in Q1 2015.
- Redmile Group's portfolio value rose 21% quarter-over-quarter to $1.11B.
Based on Redmile Group's 13F filing for Q1 2015, filed 18 May 2015.